IBIO Key Statistics, Chart & Performance
The current stock price of IBIO is 1.2 USD. In the past month the price decreased by -13.67%. In the past year, price decreased by -56.68%.
IBIO Latest News, Press Relases and Analysis
IBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About IBIO
Company Profile
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in Bryan, Texas and currently employs 20 full-time employees. The company went IPO on 2008-08-18. The firm develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
Company Info
IBIO INC
8800 HSC Pkwy
Bryan TEXAS 77807 US
CEO: Thomas F. Isett
Employees: 16
Phone: 19794460027
IBIO INC / IBIO FAQ
What does IBIO INC do?
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in Bryan, Texas and currently employs 20 full-time employees. The company went IPO on 2008-08-18. The firm develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
What is the stock price of IBIO INC today?
The current stock price of IBIO is 1.2 USD. The price decreased by -6.25% in the last trading session.
What is the dividend status of IBIO INC?
IBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of IBIO stock?
IBIO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for IBIO stock?
The Revenue of IBIO INC (IBIO) is expected to decline by -25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does IBIO INC have?
IBIO INC (IBIO) currently has 16 employees.
IBIO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to IBIO. When comparing the yearly performance of all stocks, IBIO is a bad performer in the overall market: 71.43% of all stocks are doing better.
IBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IBIO. IBIO may be in some trouble as it scores bad on both profitability and health.
IBIO Financial Highlights
Over the last trailing twelve months IBIO reported a non-GAAP Earnings per Share(EPS) of -1.57. The EPS increased by 73.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.26% | ||
| ROE | -123.5% | ||
| Debt/Equity | 0.05 |
IBIO Forecast & Estimates
10 analysts have analysed IBIO and the average price target is 4.81 USD. This implies a price increase of 301.2% is expected in the next year compared to the current price of 1.2.
For the next year, analysts expect an EPS growth of 76.89% and a revenue growth -25% for IBIO